Strides Pharma Science Friday said its step-down wholly-owned subsidiary has received approval from the US health regulator for Solifenacin Succinate tablets, used to treat overactive bladder.
The approved product is a generic version of Vesicare tablets of Astellas Pharma US, Inc.
Strides Pharma Global, Singapore, has received approval for Solifenacin Succinate tablets, 5 mg and 10 mg, from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.
Citing IQVIA data, the company said the US market for Solifenacin Succinate tablets, 5 mg and 10 mg is approximately USD 820 million.
Strides said the product will be manufactured at Alathur facility in Chennai and will be marketed by Strides Pharma in the US market.
The company's shares were trading 4.61 per cent lower at Rs 313.45 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app